Statement: Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 9/33 (27.27%)   Febrile neutropenia * 1/33 (3.03%)   Cardiac failure * 1/33 (3.03%)   Pyrexia * 2/33 (6.06%)   Chest pain * 1/33 (3.03%)   Medical device complication * 1/33 (3.03%)   Cellulitis * 1/33 (3.03%)   Sepsis * 1/33 (3.03%)   Hip fracture * 1/33 (3.03%)   Back pain * 1/33 (3.03%)   Menorrhagia * 1/33 (3.03%)   Thrombosis * 1/33 (3.03%) Adverse Events 2:
Secondary_evidence: Adverse Events 1:   Total: 10/48 (20.83%)   NEUTROPENIA 1/48 (2.08%)   THROMBOCYTOPENIA 0/48 (0.00%)   VOLUME BLOOD DECREASED 1/48 (2.08%)   FIBRILLATION ATRIAL 1/48 (2.08%)   HYPOTENSION 1/48 (2.08%)   ABDOMINAL PAIN 1/48 (2.08%)   APPETITE DECREASED 0/48 (0.00%)   DEHYDRATION 4/48 (8.33%)   DIARRHEA 4/48 (8.33%)   NAUSEA 3/48 (6.25%)   VOMITING 2/48 (4.17%)   FEVER 1/48 (2.08%)   RIGORS 0/48 (0.00%) Adverse Events 2:   Total: 5/53 (9.43%)   NEUTROPENIA 1/53 (1.89%)   THROMBOCYTOPENIA 1/53 (1.89%)   VOLUME BLOOD DECREASED 0/53 (0.00%)   FIBRILLATION ATRIAL 0/53 (0.00%)   HYPOTENSION 0/53 (0.00%)   ABDOMINAL PAIN 0/53 (0.00%)   APPETITE DECREASED 1/53 (1.89%)   DEHYDRATION 0/53 (0.00%)   DIARRHEA 0/53 (0.00%)   NAUSEA 1/53 (1.89%)   VOMITING 1/53 (1.89%)   FEVER 1/53 (1.89%)   RIGORS 1/53 (1.89%)